These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 34188271)

  • 21. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.
    Zuberbier T; Abdul Latiff AH; Abuzakouk M; Aquilina S; Asero R; Baker D; Ballmer-Weber B; Bangert C; Ben-Shoshan M; Bernstein JA; Bindslev-Jensen C; Brockow K; Brzoza Z; Chong Neto HJ; Church MK; Criado PR; Danilycheva IV; Dressler C; Ensina LF; Fonacier L; Gaskins M; Gáspár K; Gelincik A; Giménez-Arnau A; Godse K; Gonçalo M; Grattan C; Grosber M; Hamelmann E; Hébert J; Hide M; Kaplan A; Kapp A; Kessel A; Kocatürk E; Kulthanan K; Larenas-Linnemann D; Lauerma A; Leslie TA; Magerl M; Makris M; Meshkova RY; Metz M; Micallef D; Mortz CG; Nast A; Oude-Elberink H; Pawankar R; Pigatto PD; Ratti Sisa H; Rojo Gutiérrez MI; Saini SS; Schmid-Grendelmeier P; Sekerel BE; Siebenhaar F; Siiskonen H; Soria A; Staubach-Renz P; Stingeni L; Sussman G; Szegedi A; Thomsen SF; Vadasz Z; Vestergaard C; Wedi B; Zhao Z; Maurer M
    Allergy; 2022 Mar; 77(3):734-766. PubMed ID: 34536239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.
    He L; Yi W; Huang X; Long H; Lu Q
    Clin Rev Allergy Immunol; 2021 Dec; 61(3):424-448. PubMed ID: 34529248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
    Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
    JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.
    Maurer M; Zuberbier T; Metz M
    Handb Exp Pharmacol; 2022; 268():117-133. PubMed ID: 34247278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Prospective Randomized Non-Blinded Study of Safety and Efficacy of Bilastine Up-Dosing (40 mg) Versus Combination of Bilastine 20 mg With Levocetirizine 5 mg in the Treatment of Chronic Spontaneous Urticaria.
    Sneha B; Narasimhan M; Durai PCT; Ramakrishnan R
    Indian J Dermatol; 2024; 69(3):226-231. PubMed ID: 39119328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and Management of Urticaria in Indian Settings: Skin Allergy Research Society's Guideline-2022.
    Godse K; Patil A; De A; Sharma N; Rajagopalan M; Shah B; Tahiliani S; Girdhar M; Zawar V; Sangolli P; Shankar DK; Dhar S
    Indian J Dermatol; 2022; 67(6):732-743. PubMed ID: 36998850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Up-dosed Second-generation Antihistamines in Uncontrolled Chronic Spontaneous Urticaria: A Review.
    Podder I; Dhabal A; Chakraborty SS
    J Clin Aesthet Dermatol; 2023 Mar; 16(3):44-50. PubMed ID: 36950042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bilastine: a new H
    Church MK; Labeaga L
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-Life Experience of Efficacy and Safety of Bilastine in the Refractory Cases of Chronic Spontaneous Urticaria and its Effect on the Quality of Life of Patients.
    De A; Godse K; Dhoot D; Sarda A
    Indian J Dermatol; 2021; 66(2):159-164. PubMed ID: 34188271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study.
    De A; Singh S; Chakraborty D; Sarda A; Godse K
    Indian J Dermatol; 2024; 69(2):132-136. PubMed ID: 38841225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
    Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
    Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Indian Experience of Switchover to Bilastine 40 mg/day in CSU Patient Refractory to Other Antihistamines at Double Dose.
    De A; Shah B; Banodkar PD; Dhoot D; Chitnis K; Barkate H
    Indian J Dermatol; 2023; 68(6):674-677. PubMed ID: 38371575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
    Yagami A; Furue M; Togawa M; Saito A; Hide M
    J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic Urticaria: An Overview of Treatment and Recent Patents.
    Hon KL; Leung AKC; Ng WGG; Loo SK
    Recent Pat Inflamm Allergy Drug Discov; 2019; 13(1):27-37. PubMed ID: 30924425
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.